Md Mohaimenul Islam1,2, Hsuan-Chia Yang2, Phung-Anh Nguyen2, Tahmina Nasrin Poly1, Chih-Wei Huang2, Shwetambara Kekade1,2, Abdulwahed Mohammed Khalfan3, Tonmoy Debnath4, Yu-Chuan Jack Li1,2, Shabbir Syed Abdul5,6. 1. Graduate Institute of Biomedical Informatics, College of Medical Science and Technology, Taipei Medical University, 250 Wu-Hsing St., Taipei, 110, Taiwan. 2. International Center for Health Information Technology (ICHIT), Taipei Medical University, Taipei, Taiwan. 3. Department of Computing and Information Systems, College of Business Studies, PAAET, Hawalli, Kuwait. 4. Department of Public Health and Institute of Public Health, Chung Shan Medical University, Taichung, Taiwan. 5. Graduate Institute of Biomedical Informatics, College of Medical Science and Technology, Taipei Medical University, 250 Wu-Hsing St., Taipei, 110, Taiwan. drshabbir@tmu.edu.tw. 6. International Center for Health Information Technology (ICHIT), Taipei Medical University, Taipei, Taiwan. drshabbir@tmu.edu.tw.
Abstract
PURPOSE: The benefits of statin treatment for preventing cardiac disease are well established. However, preclinical studies suggested that statins may influence mammary cancer growth, but the clinical evidence is still inconsistent. We, therefore, performed an updated meta-analysis to provide a precise estimate of the risk of breast cancer in individuals undergoing statin therapy. METHODS: For this meta-analysis, we searched PubMed, the Cochrane Library, Web of Science, Embase, and CINAHL for published studies up to January 31, 2017. Articles were included if they (1) were published in English; (2) had an observational study design with individual-level exposure and outcome data, examined the effect of statin therapy, and reported the incidence of breast cancer; and (3) reported estimates of either the relative risk, odds ratios, or hazard ratios with 95% confidence intervals (CIs). We used random-effect models to pool the estimates. RESULTS: Of 2754 unique abstracts, 39 were selected for full-text review, and 36 studies reporting on 121,399 patients met all inclusion criteria. The overall pooled risks of breast cancer in patients using statins were 0.94 (95% CI 0.86-1.03) in random-effect models with significant heterogeneity between estimates (I 2 = 83.79%, p = 0.0001). However, we also stratified by region, the duration of statin therapy, methodological design, statin properties, and individual stain use. CONCLUSIONS: Our results suggest that there is no association between statin use and breast cancer risk. However, observational studies cannot clarify whether the observed epidemiologic association is a causal effect or the result of some unmeasured confounding variable. Therefore, more research is needed.
PURPOSE: The benefits of statin treatment for preventing cardiac disease are well established. However, preclinical studies suggested that statins may influence mammary cancer growth, but the clinical evidence is still inconsistent. We, therefore, performed an updated meta-analysis to provide a precise estimate of the risk of breast cancer in individuals undergoing statin therapy. METHODS: For this meta-analysis, we searched PubMed, the Cochrane Library, Web of Science, Embase, and CINAHL for published studies up to January 31, 2017. Articles were included if they (1) were published in English; (2) had an observational study design with individual-level exposure and outcome data, examined the effect of statin therapy, and reported the incidence of breast cancer; and (3) reported estimates of either the relative risk, odds ratios, or hazard ratios with 95% confidence intervals (CIs). We used random-effect models to pool the estimates. RESULTS: Of 2754 unique abstracts, 39 were selected for full-text review, and 36 studies reporting on 121,399 patients met all inclusion criteria. The overall pooled risks of breast cancer in patients using statins were 0.94 (95% CI 0.86-1.03) in random-effect models with significant heterogeneity between estimates (I 2 = 83.79%, p = 0.0001). However, we also stratified by region, the duration of statin therapy, methodological design, statin properties, and individual stain use. CONCLUSIONS: Our results suggest that there is no association between statin use and breast cancer risk. However, observational studies cannot clarify whether the observed epidemiologic association is a causal effect or the result of some unmeasured confounding variable. Therefore, more research is needed.
Entities:
Keywords:
Breast cancer; Heterogeneity; Meta-analysis; Relative risk; Statin
Authors: Xin Hong; Whijae Roh; Ryan J Sullivan; Keith H K Wong; Ben S Wittner; Hongshan Guo; Taronish D Dubash; Moshe Sade-Feldman; Benjamin Wesley; Elad Horwitz; Genevieve M Boland; Dieuwke L Marvin; Todd Bonesteel; Chenyue Lu; François Aguet; Risa Burr; Samuel S Freeman; Laxmi Parida; Katherine Calhoun; Michelle K Jewett; Linda T Nieman; Nir Hacohen; Anders M Näär; David T Ting; Mehmet Toner; Shannon L Stott; Gad Getz; Shyamala Maheswaran; Daniel A Haber Journal: Cancer Discov Date: 2020-11-17 Impact factor: 39.397
Authors: Yunan Han; Chee Teik Lee; Shuai Xu; Xiaoyue Mi; Courtnie R Phillip; Ana S Salazar; Malika Rakhmankulova; Adetunji T Toriola Journal: Breast Cancer Res Treat Date: 2021-07-01 Impact factor: 4.624